(January 11, 2017, 2:57 PM EST) -- NEW YORK — Shareholders have failed to show that a biopharmaceutical company and certain of its executive officers and directors engaged in a market manipulation scheme because the shareholders failed to identify any promotional materials that were edited or commissioned by the defendants, a federal judge in New York ruled Dec. 29 in dismissing the shareholders’ federal securities law claims and denying their request to amend (Kevin Cortina, et al. v. Anavex Life Sciences Corp., et al., No. 15-10162, S.D. N.Y.; 2016 U.S. Dist. LEXIS 179905)....